**VRIJDAG 15 februari 2019**

|  |  |
| --- | --- |
| 16:00 – 16:30 | **Ontvangst en registratie** |
| 16:30 – 16:45 | **Welkom en opening****Chairs:** Erik Cornel (ivm mogelijke afwezigheid op zaterdag) & - Toelichting op het programma en selectie van de sessies uit  het ASCO-GU programma. - Toelichting op het interactieve live programma met San Francisco  |
| 16:45 – 18:00 | **Onderwerp: prostaatkanker****Chairs:** Erik Cornel (ivm mogelijke afwezigheid op zaterdag) & **General Session 1: Optimizing Diagnosis and Treatment of Clinically Significant Nonmetastatic Prostate Cancer****[20 min]** *Update on Prostate-Specific Antigen Screening** Andrew Vickers, PhD

Memorial Sloan Kettering Cancer Center**General Session 2: General Session 2: Quality, Value, and Science for Optimizing Advanced Prostate** **Beyond Survival: Clinical Decision Making for Castrate-Sensitive Prostate Cancer****[20 min]** *Biologic Basis for Sequencing Novel Treatments for Metastatic Prostate Cancer** Himisha Beltran, MD

Dana Farber Cancer Institute**[20 min]** *Practical Application of Genomic Assays in Clinical Decision Making** Mark Rubin,
* University of Bern

**[15 min] Discussie & casus**  |
| 18:00 – 18:15 | **Pauze** |
| 18:15 – 19:45 | **Onderwerp:** **Chair:** **Oral Abstract Session A/Rapid Abstract Session A****[15 min]** **[15 min]** **[15 min]** **[15 min]** **[15 min]****[30 min] Discussie & voorbereiding voor de live sessie**  |
| 19:45 – 20:45 | **Diner** |
| 20:45 – 21:00 | **Terugkeer naar de zaal voor de live sessie** |
| 21:00 – 21:30 | **Individual live session with San Francisco**Gasten: Moderator:  |

**Zaterdag 10 februari 2018**

|  |  |
| --- | --- |
| 08:15 -08:30 | **Welkom en opening dag 2****Chair:**  |
| 08:30 – 10:45 | **Onderwerp: Blaaskanker****Chair:** **General Session 4: Challenges and Advances in Perioperative therapy for urothelial cancer****[20 min]** *Genomic Insights and Biomarkers for Treatment Selection in Muscle-Invasive and Non-Muscle-Invasive Bladder Cancer** Yair Lotan, MD –
* The University of Texas Southwestern Medical Center

**[20 min]** *Challenges of Therapy in Upper-Tract Urothelial Carcinoma** Surena F. Matin, MD, FACS –
* University of Texas MD Anderson Cancer Center

**[15 min]** *Abstract* * First Author:

**[15 min] Discussie/abstract****[15 min]** *Abstract* * First Author:

**[15 min]** *Abstract* * First Author:

**[30 min]** **Discussie en toelichting**  |
| 10:45 -11:00 | **Pauze** |
| 11:00 - 12:45 | **Onderwerp: Blaaskanker** **Chair:** **Debate: The Optimal Local Treatment for Muscle-Invasive Bladder Cancer****[15 min]** *Radical Cystectomy Is the Best Option for Muscle-Invasive Bladder Cancer** Michael Cookson, MD –
* University of Oklahoma Health Sciences Center

**[15 min]** *Trimodality Therapy Is the Best Option for Muscle-Invasive Bladder Cancer** **Jason A. Efstathiou, MD, Dphil –**
* **Massachusetts General Hospital**

**Keynote lecture****[45 min]** *Immunotherapy Across Genitourinary Malignancies** James L. Gulley, MD, PhD, FACP –
* National Cancer Institute

**[10 min]** *Abstract* * First Author:

 **[20 min] Discussie** |
| 12:45 – 13:30 | **Lunch**  |
| 13:30 – 14:15 | **Introductie & bekijken opgenomen sessie vanuit San Francisco****Onderwerp:** Gasten:Moderator:  |
| 14:15 – 15:30 | **Onderwerp: Blaaskanker & overig****Chair:** **[15 min]** *Abstract* * First Author:

**[15 min]** *Abstract* * First Author:

**[15 min]** *Abstract** First Author:

**[15 min]** *Abstract* * First Author:

**[15 min] Discussie**  |
| 15:30 – 16:00 | **Wrap-up en afsluiting****Chair:**  |

Reserve:

General Session 1: Optimizing Diagnosis and Treatment of Clinically Significant Nonmetastatic Prostate Cancer

**20 min** *Advanced Imaging and Biomarkers*

* Felix Y Feng, MD –
* University of California, San Francisco

General Session 4: Challenges and Advances in Perioperative therapy for urothelial cancer

**20 min** *Perioperative Immunotherapy in Urothelial Carcinoma: State of Existing Evidence*

* Andrea Necchi, MD - Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori

Een deel uit deze sessie; (is 1,5 uur, maar bijv. 30 minuten casus 1 of 2, op basis van scouting)

|  |  |
| --- | --- |
| General Session 5: Multimodality Treatment in Challenging Cases of urothelial carcinoma |   |
|  | Ananya Choudhury, MA, PhD, MRCP, FRCR—Chair - The Christie NHS Foundation Trust and University of Manchester |
|  | Brant Allen Inman, MD—Chair - Duke University Medical Center |
| Case Panel Discussion |   |
|  | Robert A. Huddart, MBBS, MRCP, FRCR, PhD - The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust - Radiation Oncologist |
|  | Matt D. Galsky, MD - Icahn School of Medicine at Mount Sinai - Medical Oncologist |
|  | Eila C. Skinner, MD - Stanford University - Urologist |
|  | Valeria Panebianco, MD - Sapienza University of Rome - Radiologist |